The biotech industry is experiencing a resurgence in IPO activity, characterized by a shift toward late-stage clinical assets that suggest a maturing, albeit cautious, market. Central to current industry discourse is the tension between cost-efficient global outsourcing and the national security implications of offshoring genetic engineering capabilities to China. Jason Kelly, CEO of Ginkgo Bioworks, argues that the U.S. must maintain its position at the technological frontier to avoid losing strategic control over the future of biotechnology. Meanwhile, innovation continues in oncology and virology, with Lilly aggressively expanding its vaccine portfolio, Revolution Medicines demonstrating significant survival benefits with its RAS inhibitors, and new data emerging for hepatitis B functional cures. These developments, alongside shifting FDA regulatory dynamics, underscore the industry's ongoing efforts to balance rapid clinical advancement with long-term strategic and operational sustainability.
Sign in to continue reading, translating and more.
Open full episode in Podwise